Views
8 years ago

Psicofarmacología 48

  • Text
  • Marcadores
  • Glucocorticoides
  • Eritematoso
  • Lupus
  • Psicosis
  • Snc
  • Desarrollo
  • Receptores
  • Transportadores
  • Gaba
  • Neurotransmision
  • Ciclado
  • Swich
  • Seguridad
  • Isrs
  • Litio
  • Estabilizadores
  • Antidepresivos
  • Tratamiento
  • Bipolar
Revista Latinoamericana de psicofarmacología y neurociencia.

Dr. Sergio Halsband para

Dr. Sergio Halsband para la IM y la AC en distintos tipos de pacientes y distintos ATD. Evaluar dosis eficaces para esta protección, y también si la asociación de dos drogas (dos EA o un EA más un antipsicótico atípico) puede mejorar la prevención de IM. 5) Establecer si el agregado de un antipsicótico atípico mejora la eficacia de un ISRS en la DBP y si además protege de la IM y la AC. Explorar otras combinaciones de ATD más antipsicótico atípico y eventualmente asociaciones de ATD más EA. 6) Avanzar en el conocimiento de predictores de IM y AC, ya que hasta el momento no se está seguro si los bipolares I son más “switcheadores” que los bipolares II, como así también resulta necesario establecer mejor el rol que tiene el sexo, la edad, las comorbilidades y otros factores. El mayor conocimiento de estos predictores y marcadores nos permitirá usar más y mejor los ATD en esta patología, y elegir con más precisión el ATD, la dosis, el tiempo de administración y la droga asociada. 7) Conocer con claridad el o los marcadores genéticos de la vulnerabilidad a padecer IM y AC por ATD. También es importante que se conozca mejor la fisiopatología de éstos fenómenos, lo que nos permitirá tener herramientas farmacológicas más eficaces para prevenirlos y controlarlos. En suma, los actuales conocimientos y líneas de investigación parecen preanunciar un paulatino aumento en el uso de ATD en DBP, y de un modo más confiable. Esto puede limitarse por el descubrimiento de nuevos riesgos o por la aparición de nuevas drogas más seguras y/o eficaces que los ATD para esta patología. Referencias Bibliográficas 1. Judd L, Schettler P, Akiskal H, et al. Longterm symptomatic status of bipolar I vs. bipolar II. Int J Neuropsychophamacol 2003;6:127-37. 2. Hantouche E, Akiskal H. Bipolar II vs. unipolar depression psychopathologic differentiation by dimensional measures. J Affect Disord 2005;84:127-32. 3. Ghaemi N, Douglas H, Soldani F, Goodwin F. Antidepressants in bipolar disorders: the case for caution. Bipolar Disorders 2003;5:421-33. 4. Moller H, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000;250:57- 68. 5. Amsterdam J, Brunswick D. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disorders 2003;5:388-95. 6. Baunhackl V, Bizierek, Fischbach R, et al Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder DSM III); an Austrian double- blind-multicentre study. Br J Psychiatry 1989;155(Suppl. 6):78- 83. 7. Himmelhoch J, Thase M, Mallinger A, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression Am J Psychiatry 1991;148:910-6. 8. Thase M, Frank E, Mallinger A, et al. Treatment of imipramine- resistant recurrent depression: III. Efficacy of monamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11. 9. Fogelson Dl, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: The same old story? J Clin Psychiatry 1992;53:443-6. 10. Sachs G, Lafer B, Stoll A, et al. A doubleblind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3. 11. Cohn J. Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-22. 12. El- Mallakh R, Karippot A, Ghaemi N. Antidepressants in bipolar depression. En: El- Mallakh R, Ghaemi V eds. Bipolar Depression, Washington; Am Psychiatric Publishing, 2006;167–83. 13. Nemeroff C, Evans D, Gyulai L. Double- Blind, Placebo Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression. Am J Psychiatry 2001;158:906-12. 14. Fonseca M, Soares J, Hatch J. An Open Trial of Adjunctive Escitalopram in Bipolar Depression. J Clin Psychiatry 2006;67;1:81–6. 15. Vieta E, Martínez-Arán A, Goikolea J. A randomized Trial Comparing Paroxetine and Venlafaxine in the Treatment of Bipolar Depressed Patients Taking Mood Stabilizers. J Clin Psychiatry 2002;63(6):508–12. 16. Young L, Joffe, Robb R, et al. Double–blind comparison of addition of a second mood–stabilizer versus an antidepressant to an initial mood–stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-26. 17. Gijsman H, Geddes J, Rendell J, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47. 18. Amsterdam J, García-España F, Fawcet J, et al. Efficacy and safety of fluoxetine in bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:435-40. 19. Amsterdam J, Shults J, Brunswick D, Hundert M. Short term fluoxetine monotherapy for bipolar type II or bipolar NOS mayor depression- Low manic switch rate. Bipolar Disorders 2004;6: 75-81. 20. Amsterdam J. Efficacy and Safety of venlafaxine in bipolar type II major depressive episode. J Clin Psychopharmacol 1998;18:414-7. 21. Moller H, Bottlender R, Grunze H. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord 2001;67:141-6. 22. Ghaemi N, Rosenquist K, et al. Antidepressant Treatment in Bipolar vs. Unipolar Depression Am J Psychiatry 2004;161:163-5. 23. Tohen M, Vieta E, Calabrese J, et al. Efficacy of Olanzapine and Olanzapine- Fluoxetine Combination in the Treatment of Bipolar I Depression. Arch Gen Psychiatry 2003;60:1079–88. 24. Corya S, Perlis R, Keck P, et al. A 24-week Open Label Extension study of Olanzapine Monotherapy in the Treatment of Bipolar Depression. J Clin Psychiatry 2006;67:798- 806. 25. Brown E, Mc. Elroy S, Keck P, et al. A 7 Week, Randomized, Double-Blind Trial of Olanzapine/Fluoxetine Combination versus Lamotrigine in the Treatment of Bipolar I Depression J Clin Psychiatry 2006;67:1025- 33. 26. Adams D, Degenhardt E, Tohen M, et al. Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Long- Term Treatment of Bipolar I Depression. Poster presentado en: Fifth European Stanley Conference on Bipolar Disorder ESCBD / Stanley) October 5- 7,2006;Barcelona, Spain. 27. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-9. 28. Koch. Perry S, Bymaster KW. Brain re¬gion and dose effects of an olanzapina/fluo¬xetine combination on extracellular mono¬amine concentrations in the rat. Neuropharmacol 2004;46:232-42. 29. Yatham LN, Goldstein JM, Vieta. E, et al. Atypical antipsychotics in bipolar depression: Potential mechanisms of action. J Clin Psychiatry 2005;66(Suppl 5):40-8. 30. Amsterdam J, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression–lack of manic induction. J Affect Disord 2005;87:121-30. 31. Shelton R, Stahl S. Risperidone and Paroxetine Given Singly and in Combination for Bipolar Depression. J Clin Psychiatry 2004;65:12:1715-9. 32. Ghaemi N, Lenox M, Baldessarini R. Effectiveness and Safety of Long- Term Antidepressant Treatment in Bipolar Disorder. J Clin Psychiatry 2001;62;7:565-9. 33. Fu A, Christensen D, Hansen R. Second Generation Antidepressant Discontinuation and Depressive Relapse in Adult Patients with Bipolar Depression: Results of o Retrospective Database Analysis. Clin Therap 2006;28;6:979-89. 34. Akiskal H, Akiskal K, Lancrenon S, et al. Validating the bipolar spectrum in the French National EPIDEP Study: Overview of the phenomenology and relative prevalence of its clinical prototypes. J Affect Disord 2006;96:197- 205. 35. Akiskal H, Bourgeois M, Angst J, et al. Re. evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorder. J Affect Disord 2000;59:55- 18 // EDITORIAL SCIENS

Psicofarmacología 8:48, Febrero 2008 530. 36. Serretti A, Artioli P, Zanardi R, et al. Genetic features of antidepressant induced mania and hypomania in bipolar disorder. Psychopharmacol 2004;174;4:504-11. 37. Wehr T, Goodwin F. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-11. 38. Angst J. Switch from depression to mania–a record study over decades between 1920 and 1982. Psychopathology 1985;18:140-54. 39. Prien R, Klett C, Caffey E. Lithium carbonate and imipramine in prevention of affective episodes. Arch Gen Psychiatry 1973;29:420-5. 40. Quitkin F, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar I patients. Arch Gen Psychiatry 1981;38:902-7. 41. Post R, Altshuler L, Leverich G, et al. Comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131. 42. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549- 550. 43. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRI as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord 2006;92:205-14. 44. Keck P, Corya S, Altshuler L. Analyses of Treatment–Emergent Mania with Olanzapine/Fluoxetine Combination in the Treatment of Bipolar Depression. J Clin Psychiatry 2005;66(5):611-6. 45. Gabbay V, O`Dowd M, Asais G. Combined Antidepressant Treatment: A Risk Factor for Switching in Bipolar Patients. J Clin Psychiatry 2002;63(4):367-8. 46. Goren J, Levin G. Mania with bupropion. A dose related phenomenon? Ann Pharmacother 2000;24(5):619-21. 47. Stoll A, Mayer P, Kolbrener M, et al. Antidepressant- associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry 1994;151:1642-5. 48. El- Mallakh R. Bupropion manic induction during euthymia, but not during depression. Bipolar Disorders 2001;3:259-65. 49. Ostacher M. The Evidence for Antidepressant Use in Bipolar Depression, J Clin Psychiatry 2006;67(Suppl 11):18-21. 50. Jann M, Bitar A, Rao A. Lithium prophylaxis of tricyclic- antidepressant- induced mania in bipolar patients. Am J Psychiatry 1982;139:683-4. 51. Prien R, Kupfer D, Mansky P, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine and a lithium carbonate-imipramine combination Arch Gen Psychiatry 1984;41:1096-104. 52. Bottlender R, Rudolf D, Strauss A, Möller H. Mood-stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disorders 2001;63:79-83. 53. Henry C, Demotes-Mainard J. Avoiding Drug-Induced Switching in Patients- with Bipolar Depression. Drug Safety 2003;26(5):337-51. 54. Nelson J, Schottenfield R, Conrad E. Hypomania after desipramine withdrawal. Am J Psychiatry 1983;140:624-5. 55. Disalver S. Antidepressant withdrawal. Syndromes: phenomenology and patophysiology. Acta Psychiatr Scand 1989;79:113-7. 56. Henry C. SSRI and induction of manic episode. J Clin Psychiatry 2002;63 (4):367-8 57. Kukopulos A, Caliari B, Tundi A, et al. Rapid cyclers, Temperament and antidepressants. Comprehen Psychiatry 1983;24:249-58. 58. Wehr T, Sack D, Rosenthal N, et al. Rapid cycling affective disorder: contributing factors and treatment response in 51 patients. Am J Psychiatry 1988;145:179-84. 59. Ghaemi S, Boiman E, Goodwin F. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-8. 60. Altshuler L, Post R, Leverich G. Antidepressant–induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8. 61. Joffe R, Mac Queen G, Marriott M, et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressants. Acta Psychiatr Scand 2002;105:429-30. 62. Desarkar P, Bakhla A, Kumar Sinha V. Duloxetine-Induced Ultrarapid Cycling in an Adolescent With Bipolar Depression. J Clin Psychopharmachol 2007;27:115-6. 63. El-Mallakh R, Karippot A. Chronic Depression in Bipolar Disorder. Am J Psychiatry 2006;163(8):1337-41. 64. El-Mallakh R, Karippot A. Antidepressantassociated chronic dysphoria (ACID) in bipolar disorders. J Affect Disord 2005;84:267-272. 65. Moller H, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000;250:57- 68. 66. Mc Elroy S, Kotwal R, Kaneria R, Keck P. Antidepressants and suicidal behavior in bipolar disorder. Bipolar Disorders 2006;8:596-617. 67. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-course mortality in patients with mood disorders: a systematic review of randomized trials Am J Psychiatry 2005;162:1805-19. 68. Goldberg J, Garno J, Portera L, et al. Correlates of suicidal ideation in dysphoric mania. J Affect Disord 1999;56:75-81. 69. Goldberg J, Allen M, Miklowitz D, et al. Suicidal ideation and pharmacotherapy among STEP- BD patients. Psychiatr Serv 2005;56:1534–40. 70. Bauer M, Wisniewski S, Marangell L, et al. Are Antidepressants Associated With New-Onset Suicidality in Bipolar Disorder? A Prospective Study of Participants in The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP- BD). J Clin Psychiatry 2006;67;1:48-55. 71. Goldberg J. Ghaemi N. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disorders 2005;7(suppl 5):3-12. 72. Fountoulakis K, Vieta E, Sanchez- Moreno J, et al. Treatment guidelines for bipolar disorder: A critical review. J of Affective Disord 2005;86:1-10. 73. http://www.dshs.state.tx.us/mhprograms /TIMA.shtm> [Consulta en marzo de 2007]. 74. [Consulta en marzo de 2007]. 75. Henry C, Sorbara F, Lacoste J, et al. Antidepressant- Induced Mania in bipolar Patients: Identification of Risk Factors. J Clin Psychiatry 2001;62(4):249-54. 76. Suppes T, Kelly D, Perla J. Challenges in the Management of Bipolar Depression. J Clin Psychiatry 2005;66(suppl 5):11-6. 77. Benazzi F. Antidepressant- associated hypomania in outpatient depression: a 203-case study in private practice. .J Affect Disord 1997;46:73-7. 78. Serretti A, Artioli P, Zanardi R, Rossini D. Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Progr Neuro–Psychopharmacol & Biol Psychiatry 2003;27:751-7. 79. Leverich G, Altshuler L, Frye M et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;63(2):232-9. 80. Bottlender R, Sato T, Kleindienst N, et al. Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. J of Affect Disord 2004;78:149-52. 81. Mc Queen G, Young L, Marriott M et al. Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatr Scand 2002;15:414-8. 82. Boerlin H, Gitlin M, Zoellner L, et al. Bipolar depression and antidepressant -induced mania: a naturalistic study. J Clin Psychiatry 1998;59:374-9. 83. Howland R. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16:425-7. 84. Fagiolini A, Frank E, Cherry C et al. Clinical indicators for the use of antidepressants in the treatment of bipolar I depression. Bipolar Disorders 2002;4:277-82. 85. Goldberg J, Whiteside J. The Association between substance abuse and antidepressantinduced mania in bipolar disorder. J Clin Psychiatry 2002;63;9:791-5. 86. Manwani S, Pardo T, Albanese M. Substance Use Disorder and Other Predictors of Antidepressant–Induced Mania: A Retrospective Chart Review. J Clin Psychiatry 2006;67:1341- 5. 87. Mundo E, Walker M, Cate T, et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001;58:539-44. 88. www.preskorn.com Applied Clinical Psychopharmacology [Consulta en marzo de 2007]. Disponible en URL< http://www.preskorn.com/bio.html EDITORIAL SCIENS // 19

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015